Compare Jins Holdings, Inc. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 29.40%
- Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 44.88
2
The company has declared Positive results for the last 8 consecutive quarters
3
With ROCE of 42.06%, it has a attractive valuation with a 4.34 Enterprise value to Capital Employed
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 158,028 Million (Small Cap)
14.00
NA
0.00%
-0.11
25.22%
4.66
Revenue and Profits:
Net Sales:
26,525 Million
(Quarterly Results - Feb 2026)
Net Profit:
1,930 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
25.53%
0%
25.53%
6 Months
-4.8%
0%
-4.8%
1 Year
-27.89%
0%
-27.89%
2 Years
89.57%
0%
89.57%
3 Years
111.99%
0%
111.99%
4 Years
55.34%
0%
55.34%
5 Years
-16.15%
0%
-16.15%
Jins Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.74%
EBIT Growth (5y)
16.74%
EBIT to Interest (avg)
44.88
Debt to EBITDA (avg)
0.10
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
2.41
Tax Ratio
31.40%
Dividend Payout Ratio
30.54%
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
29.40%
ROE (avg)
18.39%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
4.03
EV to EBIT
10.32
EV to EBITDA
8.24
EV to Capital Employed
4.34
EV to Sales
1.25
PEG Ratio
0.27
Dividend Yield
NA
ROCE (Latest)
42.06%
ROE (Latest)
28.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : May 2015
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.03%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Feb'26 - QoQ
Feb'26
Nov'25
Change(%)
Net Sales
26,525.00
23,987.00
10.58%
Operating Profit (PBDIT) excl Other Income
3,786.00
2,825.00
34.02%
Interest
49.00
44.00
11.36%
Exceptional Items
-110.00
-3.00
-3,566.67%
Consolidate Net Profit
1,930.00
1,463.00
31.92%
Operating Profit Margin (Excl OI)
109.70%
84.40%
2.53%
USD in Million.
Net Sales
QoQ Growth in quarter ended Feb 2026 is 10.58% vs -12.46% in Nov 2025
Consolidated Net Profit
QoQ Growth in quarter ended Feb 2026 is 31.92% vs -28.46% in Nov 2025
Annual Results Snapshot (Consolidated) - Aug'25
Aug'25
Aug'24
Change(%)
Net Sales
97,215.00
82,999.00
17.13%
Operating Profit (PBDIT) excl Other Income
15,041.00
10,763.00
39.75%
Interest
155.00
129.00
20.16%
Exceptional Items
-653.00
-773.00
15.52%
Consolidate Net Profit
8,330.00
4,671.00
78.33%
Operating Profit Margin (Excl OI)
124.40%
94.40%
3.00%
USD in Million.
Net Sales
YoY Growth in year ended Aug 2025 is 17.13% vs 13.29% in Aug 2024
Consolidated Net Profit
YoY Growth in year ended Aug 2025 is 78.33% vs 165.10% in Aug 2024
About Jins Holdings, Inc. 
Jins Holdings, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






